4-bromo-2-(methoxymethoxy)benzaldehyde | 194163-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-bromo-2-(methoxymethoxy)benzaldehyde
• CAS: 194163-05-8
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: YFFYGBPVWBYDRM-UHFFFAOYSA-N

物化性质

• 沸点：
  329.3±37.0 °C(Predicted)
• 密度：
  1.492±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(methoxymethoxy)benzaldehyde 在 copper(l) iodide 、 水 、 potassium carbonate 、 对甲苯磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium iodide 作用下， 以 1,4-二氧六环 为溶剂， 生成 ethyl 6-cyano-2-benzofurancarboxylate
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  2-羟基-4-溴苯甲酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 硫酸 、 sodium hydride 作用下， 生成 4-bromo-2-(methoxymethoxy)benzaldehyde
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k

文献信息

• Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis
  作者：Shengtian Cao、Xinye Yang、Zheng Zhang、Junwen Wu、Bo Chi、Hong Chen、Jianghong Yu、Shanshan Feng、Yulin Xu、Jing Li、Yingjun Zhang、Xiaojun Wang、Yan Wang

  DOI：10.1016/j.ejmech.2021.114089

  日期：2022.2

  NAFLD, can develop into cirrhosis and hepatocellular cancer. Unfortunately, current options for therapeutic treatment of NASH are very limited. Among multiple pathways in NASH, farnesoid X receptor (FXR), a nuclear bile acid receptor, is well-recognized as an important effective target. Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior

  非酒精性脂肪性肝病 (NAFLD) 正在成为全球慢性肝病最主要的负担。非酒精性脂肪性肝炎 (NASH) 是 NAFLD 的进行性形式，可发展为肝硬化和肝细胞癌。不幸的是，目前 NASH 治疗的选择非常有限。在 NASH 的多种途径中，法尼醇 X 受体 (FXR)，一种核胆汁酸受体，被公认为重要的有效靶点。在这里，我们报告了基于先前的高亲和力非甾体分子 GW4064 的新型三环 FXR 激动剂化合物 HEC96719 的合成和表征。HEC96719在体外和体内表现出优于 GW4064 和奥贝胆酸的优异效力FXR活化的测定。它还显示出更高的 FXR 选择性和更有利的组织分布，主要在肝脏和肠道中。关于药代动力学特性、疗效和安全性的临床前数据总体表明，HEC96719 是一种有前途的 NASH 治疗候选药物。
• Metal-dependent selective formation of calix[4]arene assemblies based on dynamic covalent chemistry
  作者：Yoko Sakata、Ryo Tsuyuki、Shingo Sugimoto、Shigehisa Akine

  DOI：10.1039/d1cc05553d

  日期：——

  The reaction of calix[4]arene derivatives 1a and 1b bearing four salicylaldehyde moieties with 1,3-propanediamine gave macrocyclic trimers 5a and 5b, respectively, which have intramolecular bridges formed via the flattened cone conformation. In contrast, a capsular-shaped dimeric cage [7a·2Na]2+ was selectively formed when the conformation of the calix[4]arene moiety of 1a was fixed in the spread cone

  杯[4]的反应芳烃衍生物1a和1b轴承4的水杨醛部分与1,3-丙二胺，得到大环三聚体5a和5b，分别具有形成分子内桥经由该扁平锥体构象。相比之下，当1a的杯[4]芳烃部分的构象通过与下缘酰胺的Na +络合固定在展开的锥形构象中时，选择性地形成荚膜形二聚体笼[ 7a ·2Na] 2+组。
• Tricyclic compounds and uses thereof in medicine
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US10183917B2

  公开（公告）日：2019-01-22

  The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

  本发明涉及能与FXR结合并作为FXR调节剂的新型三环化合物，或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶质、代谢物、药学上可接受的盐或原药，以及该化合物用于治疗由FXR介导的疾病和/或病症的用途。本发明进一步提供了一种含有本文公开的化合物的药物组合物，以及一种治疗由FXR介导的疾病和/或病症的方法，该方法包括施用该化合物或药物组合物。
• Nitrogen-containing tricyclic compounds and uses thereof in medicine
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US10562910B2

  公开（公告）日：2020-02-18

  A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

  本发明描述了一种作为 FXR 调节剂的含氮三环化合物，或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶解物、代谢物、药学上可接受的盐或原药，以及该化合物用于治疗由 FXR 介导的疾病和/或状况的用途。此外，还描述了含有本文公开的化合物的药物组合物，以及通过施用该化合物或其药物组合物治疗由 FXR 介导的疾病和/或病症的方法。
• WO2020010252A5
  申请人：——

  公开号：WO2020010252A5

  公开（公告）日：2022-07-05